Table 2 Adjusted mean difference versus placebo (95% two-sided CI) in adjusted mean change from baseline to final visit for number of incontinence episodes/24 h and number of micturitions/24 h for subgroups of patients who received prior antimuscarinic OAB medication; who discontinued it because of either insufficient efficacy or poor tolerability; and for those who were antimuscarinic treatment-naïve
Incontinence episodes/24 h (FAS-I) | Micturitions/24 h (FAS) | |||||
|---|---|---|---|---|---|---|
Mirabegron 50 mg | Mirabegron 100 mg | Tolterodine ER 4 mg | Mirabegron 50 mg | Mirabegron 100 mg | Tolterodine ER 4 mg | |
Patient subgroup | ||||||
Received prior antimuscarinic OAB medication and discontinued | −0.48 (–0.90, –0.06) | −0.39 (–0.81, 0.02) | −0.10 (–0.52, 0.32) | −0.68 (–1.12, –0.25) | −0.51 (–0.94, –0.08) | −0.20 (–0.64, 0.23) |
Discontinued* due to: | ||||||
Insufficient efficacy | −0.76 (–1.32, –0.19) | −0.62 (–1.16, –0.07) | −0.06 (–0.63, 0.50) | −0.59 (–1.15, –0.04) | −0.58 (–1.13, –0.02) | −0.08 (–0.64, 0.47) |
Poor tolerability | −0.24 (–1.09, 0.61) | −0.14 (–1.01, 0.73) | −0.41 (–1.28, 0.46) | −0.77 (–1.64, 0.09) | −0.75 (–1.61, 0.12) | −0.18 (–1.08, 0.71) |
Antimuscarinic treatment-naïve patients | −0.29 (–0.77, 0.18) | −0.15 (–0.64, 0.34) | −0.08 (–0.55, 0.39) | −0.52 (–0.95, –0.09) | −0.37 (–0.80, 0.06) | −0.29 (–0.71, 0.14) |